Myelodysplastic Syndrome
Conference Coverage
Combo proves most effective in HMA-naive, higher-risk MDS
NEWPORT BEACH, CALIF. – Oral rigosertib plus azacitidine produced a 90% response rate in higher-risk patients with myelodysplastic syndromes who...
Conference Coverage
More abnormal cells linked to poorer ASCT outcomes in MDS
NEWPORT BEACH, CALIF. – Patients with more than 60% cytogenetically abnormal cells at transplant had inferior overall survival and relapse-free...
Conference Coverage
Model inspired by Netflix, Amazon may help guide MDS treatment
NEWPORT BEACH, CALIF. – The researchers used an algorithm to help predict response or resistance to lenalidomide with a high degree of accuracy....
Conference Coverage
Sorafenib plus GCLAM held safe in AML, MDS phase-1 study
NEWPORT BEACH, CALIF. – Sorafenib plus GCLAM has shown promise in a phase 1 trial of patients with AML and MDS.
News
Chemo for solid tumors and risk of tMDS/AML
Chemotherapy for solid tumors is associated with an increased risk of therapy-related myelodysplastic syndromes or acute myeloid leukemia (tMDS/...
Video
Model bests IPSS-R for predicting survival, risk for AML in myelodysplastic syndrome
News
Luspatercept reduced transfusion burden in MDS patients
SAN DIEGO—Results of the randomized, phase 3 Medalist trial show that the erythroid maturation agent luspatercept can reduce transfusion burden in...
Conference Coverage
MEDALIST: Erythroid maturation agent reduced transfusion burden in MDS
SAN DIEGO – Luspatercept also showed promise in a phase 3 trial including adults with beta-thalassemia.
Conference Coverage
Your guide to ASH 2018: Abstracts to watch
News
FDA approves emapalumab for primary HLH
Emapalumab (Gamifant) is expected to be available in the U.S. in the first quarter of 2019.
News
FDA approves generic decitabine for MDS
The U.S. Food and Drug Administration has approved Lupin’s decitabine product, a generic version of Otsuka Pharmaceutical Co.